Thomasville National Bank Buys 1,900 Shares of Novartis AG (NYSE:NVS)

Thomasville National Bank lifted its stake in Novartis AG (NYSE:NVS) by 28.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,475 shares of the company’s stock after buying an additional 1,900 shares during the quarter. Thomasville National Bank’s holdings in Novartis were worth $699,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Argent Advisors Inc. grew its position in shares of Novartis by 3.3% during the fourth quarter. Argent Advisors Inc. now owns 3,719 shares of the company’s stock worth $351,000 after purchasing an additional 118 shares in the last quarter. STA Wealth Management LLC grew its holdings in Novartis by 2.2% during the 4th quarter. STA Wealth Management LLC now owns 5,666 shares of the company’s stock valued at $535,000 after buying an additional 120 shares in the last quarter. 9258 Wealth Management LLC grew its holdings in Novartis by 3.5% during the 4th quarter. 9258 Wealth Management LLC now owns 3,593 shares of the company’s stock valued at $339,000 after buying an additional 120 shares in the last quarter. Mid Atlantic Financial Management Inc. ADV grew its holdings in Novartis by 2.8% during the 4th quarter. Mid Atlantic Financial Management Inc. ADV now owns 4,647 shares of the company’s stock valued at $439,000 after buying an additional 125 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in Novartis by 3.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,719 shares of the company’s stock valued at $352,000 after buying an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 9.86% of the company’s stock.

Shares of NYSE:NVS opened at $86.30 on Thursday. Novartis AG has a 12-month low of $77.04 and a 12-month high of $98.52. The business’s fifty day simple moving average is $86.31 and its 200-day simple moving average is $88.58. The company has a market capitalization of $197.51 billion, a PE ratio of 27.93, a P/E/G ratio of 1.76 and a beta of 0.59. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.49.

Novartis (NYSE:NVS) last announced its earnings results on Monday, January 25th. The company reported $1.34 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by ($0.03). Novartis had a return on equity of 24.39% and a net margin of 14.71%. The business had revenue of $12.77 billion for the quarter, compared to analysts’ expectations of $12.86 billion. During the same quarter last year, the firm earned $1.32 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Research analysts predict that Novartis AG will post 5.8 EPS for the current year.

The company also recently declared an annual dividend, which was paid on Monday, March 15th. Shareholders of record on Friday, March 5th were paid a dividend of $3.3784 per share. This represents a yield of 2.2%. The ex-dividend date of this dividend was Thursday, March 4th. This is an increase from Novartis’s previous annual dividend of $3.04. Novartis’s payout ratio is presently 39.69%.

A number of equities analysts have recently commented on the company. Cowen cut Novartis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $110.00 to $105.00 in a report on Monday, February 1st. Morgan Stanley reissued an “overweight” rating on shares of Novartis in a research note on Tuesday, February 2nd. Barclays reissued an “underweight” rating on shares of Novartis in a research note on Friday, January 22nd. Deutsche Bank Aktiengesellschaft started coverage on Novartis in a research note on Friday, January 15th. They set a “buy” rating for the company. Finally, Sanford C. Bernstein started coverage on Novartis in a research report on Monday, March 22nd. They set a “market perform” rating for the company. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $108.50.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.

Recommended Story: Trading Halts Explained

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.